Omeros (NASDAQ:OMER) Lowered to "Sell" Rating by StockNews.com

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by equities research analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Wednesday.

A number of other analysts have also recently commented on OMER. RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a "buy" rating and a $9.00 price target for the company. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and an average price target of $22.50.

Omeros Stock Up 2.5 %

OMER traded up $0.19 during trading hours on Wednesday, hitting $7.66. 657,069 shares of the company's stock were exchanged, compared to its average volume of 529,739. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The stock's 50-day moving average is $9.04 and its two-hundred day moving average is $7.05. The stock has a market cap of $443.90 million, a price-to-earnings ratio of -3.32 and a beta of 2.03.

Remove Ads

Institutional Trading of Omeros

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its stake in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company's stock worth $5,318,000 after buying an additional 6,839 shares during the last quarter. State Street Corp lifted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after buying an additional 3,839 shares during the last quarter. Nomura Holdings Inc. lifted its stake in shares of Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after buying an additional 430,932 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company's stock worth $1,926,000 after buying an additional 18,454 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Omeros by 8.8% during the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock worth $1,610,000 after buying an additional 13,201 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.